Drug Trial Radar · NCT06333314
Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
Last checked: Nov 20, 2026Latest source record: Dec 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Jul 23, 2024
Primary completion
Oct 2028
Study completion Sep 2030
Sponsor
- Lead sponsor
- UNICANCERAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute, France; GlaxoSmithKline
- First posted
- Mar 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this open-label randomized, multicenter, comparative phase II trial is to evaluate the efficacy of the immunotherapy, dostarlimab, as first-line treatment for deficient mismatch repair (dMMR)/microsatellite instability (MSI) non-resectable metastatic or locally advanced non-colorectal and non-endometrial cancers compared to the standard of care chemotherapy. Adult patients (aged ≥18 years) with histologically confirmed dMMR/MSI duodenum and small bowel adenocarcinoma, gastric and oeso-gastric junction (OGJ) adenocarcinoma with combined positive score (CPS)\<5, pancreatic adenocarcinoma, ampulla of vater adenocarcinoma, adrenocortical carcinoma, carcinoma of unknown primary site, neuroendocrine carcinoma (Grade3) all primary, and soft tissue sarcoma (except Gastro-Intestinal Stromal Tumor) will be included in this study. They will be randomized and treated with either dostarlimab (experimental arm A), or chemotherapy (control arm B). Patients with documented disease progression following the first line chemotherapy (Arm B) may be eligible for crossover to be treated with dostarlimab, with the same schedule as arm A.
Conditions
- Pancreatic Adenocarcinoma
- Ampulla of Vater Carcinoma
- Adrenocortical Carcinoma
- Neuroendocrine Carcinoma
- Soft Tissue Sarcoma
- Small Bowel Adenocarcinoma
- Duodenum Adenocarcinoma
- Gastric Adenocarcinoma
Interventions
DostarlimabDrug
Anti-PD-1 monoclonal antibody
ChemotherapyDrug
* mFOLFOX6 or FOLFIRI or XELOX regimen * FOLFOX or XELOX or TFOX regimen * FOLFIRINOX or gemcitabine-nab-paclitaxel or gemcitabine monotherapy. * Cisplatin and gemcitabine cisplatin or CAPOX or mFOLFOX6. * Etoposide-cisplatin-doxorubicin or mitotane * Cisplatin and gemcitabine or carboplatin and paclitaxel * Etoposide-cisplatin or etoposide-carboplatin * Doxorubicin and ifosfamide or doxorubicin monotherapy or doxorubicin and trabectedin.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survivalTime frame: From randomization until disease progression or death from any cause, up to 3 years.
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
Institut de Cancérologie de l'Ouest
Angers, France · Not yet recruiting
Institut du Cancer Avignon-Provence
Avignon, France · Not yet recruiting
CHU Jean Minjoz
Besançon, France · Not yet recruiting
CHU Morvan
Brest, France · Not yet recruiting
Centre François Baclesse
Caen, France · Not yet recruiting
Centre Jean Perrin
Clermont-Ferrand, France · Not yet recruiting
CHU - Henri Mondor
Créteil, France · Not yet recruiting
Centre Georges François Leclerc
Dijon, France · Not yet recruiting
Centre Léon Bérard
Lyon, France · Recruiting
Hôpital la Timone
Marseille, France · Not yet recruiting
Institut Paoli Calmettes
Marseille, France · Not yet recruiting
Institut de Cancérologie de Lorraine
Nancy, France · Not yet recruiting
Institut Mutualiste Montsouris
Paris, France · Not yet recruiting
CHU de Bordeaux - Hôpital Haut -Lèvêque
Pessac, France · Not yet recruiting
CHU de Poitiers
Poitiers, France · Not yet recruiting
Institut Jean Godinot
Reims, France · Not yet recruiting
Centre Eugène Marquis
Rennes, France · Not yet recruiting
CHU de Rouen
Rouen, France · Not yet recruiting
Institut de Cancérologie de l'Ouest
Saint-Herblain, France · Not yet recruiting
CHU de Toulouse Hôpital Rangueil
Toulouse, France · Not yet recruiting
Gustave Roussy Grand Paris
Villejuif, France · Not yet recruiting
Hôpital Saint-Antoine
Paris, Île-de-France Region, France · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.